Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: Randomized controlled trial
Malaria Journal, Volume 5, Article 43, Year 2006
Notification
URL copied to clipboard!
Description
Background: The therapeutic efficacy of artesunate plus amodiaquine and artemether/ lumefantrine were assessed in an area of Nigeria with high levels of Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine. Participants: Children aged 6 to 59 months with uncomplicated P. falciparum infection and parasite density 1,000 to 200,000 parasites/μL enrolled following informed consent by parents. Methods: Eligible children were randomly assigned to receive either a 3-day course of artesunate (4 mg/kg) plus amodiaquine (10 mg/kg) or 6-dose course of artemether/lumefantrine (20/120 mg tablets) over three days. Patients were followed up with clinical and laboratory assessments until day 14 using standard WHO in-vivo antimalarial drug test protocol. Results: A total 119 eligible children were enrolled but 111 completed the study. Adequate clinical and parasitological response (ACPR) was 47 (87.0%) and 47 (82.5%) for artemether-lumefantrine (AL) and artesunate+amodiaquine (AAMQ) respectively (OR 0.7, 95% confidence interval 0.22 to 2.22). Early treatment failure (ETF) occurred in one participant (1.8%) treated with AAQ but in none of those with AL. Two (3.7%) patients in the AL group and none in the AAQ group had late clinical failure. Late parasitological failure was observed in 9 (15.8) and 5 (9.3%) of patients treated with AAQ and AL respectively. None of participants had a serious adverse event. Conclusion: Artemether- lumenfantrine and artesunate plus amodiaquine have high and comparable cure rates and tolerability among under-five children in Calabar, Nigeria. © 2006 Meremikwu et al; licensee BioMed Central Ltd.
Authors & Co-Authors
Meremikwu, Martin Madu
Nigeria, Calabar
Institute of Tropical Diseases Research and Prevention
Alaribe, Ambrose Andrew Anyanwu
Nigeria, Calabar
Institute of Tropical Diseases Research and Prevention
Ejemot-Nwadiaro, Regina I.
Nigeria, Calabar
Institute of Tropical Diseases Research and Prevention
Oyo-Ita, Angela Ekanem
Nigeria, Calabar
Institute of Tropical Diseases Research and Prevention
Ekenjoku, John
Nigeria, Calabar
Institute of Tropical Diseases Research and Prevention
Nwachukwu, Chukwuemeka E.
Nigeria, Calabar
Institute of Tropical Diseases Research and Prevention
Ordu, Donald
Nigeria, Abuja
Federal Ministry of Health
Ezedinachi, Emmanuel N.U.
Nigeria, Calabar
Institute of Tropical Diseases Research and Prevention
Statistics
Citations: 64
Authors: 8
Affiliations: 2
Identifiers
Doi:
10.1186/1475-2875-5-43
ISSN:
14752875
e-ISSN:
14752875
Research Areas
Infectious Diseases
Maternal And Child Health
Study Approach
Quantitative
Study Locations
Nigeria